What kind of medicine does Sotolaxib belong to, and what is its effect? How much can you buy it for now?

Sotorasib (Sotorasib), also known as AMG510, is an innovative small molecule targeted drug specifically designed to target the KRAS G12C gene mutation. KRAS G12C mutation is a common driver gene mutation in various cancers, especially non-small cell lung cancer. Traditional treatments are often difficult to effectively respond to it. The advent of sotorasibu has brought unprecedented treatment hope to KRAS mutant cancer patients around the world.

From a mechanism of action, sotorasiib binds toKRAS G12C protein, locking it in an inactive state, thereby preventing it from sending out uncontrolled cell growth signals. This precisely targeted treatment method not only avoids the impact on unmutated KRAS protein, but also significantly improves the therapeutic effect and reduces toxic and side effects. Clinical studies have shown that sotorasiib has shown excellent efficacy in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations, with an overall response rate (ORR) as high as 36% and a median duration of response of up to 10 months.

Regarding price, the price of Sotoraxibu varies depending on the region, version and purchase channel. Domestically, although sotorasibu has not yet been approved for marketing by the National Medical Products Administration (NMPA), many patients have been exposed to this drug through overseas channels or participation in clinical trials. It is understood that the price of the overseas original version of sotorasibu is relatively high, while the generic version is relatively close to the people. For example, the version produced by Lucius Pharmaceuticals costs about one to two thousand yuan per box (120mg*56 tablets). The specific price needs to be determined according to the patient's region, purchasing channel and other factors.

To sum up, as a targeted drug againstKRAS G12C mutation, sotoracib brings new hope to cancer patients with its excellent therapeutic effect and low toxic side effects. Although the current price factor still needs to be considered, with the advancement of medical technology and the improvement of the drug approval process, it is believed that sotoracib will become more popular and bring treatment hope to more patients.